Silexion Therapeutics Bolsters Financial Position with $3.3 Million Warrant Exercise

Silexion Therapeutics Corp (NASDAQ: SLXN), a clinical-stage biotech company specializing in RNA interference (RNAi) therapies for KRAS-driven cancers, has announced the exercise of warrants for approximately $3.3 million in gross proceeds. This strategic move is expected to strengthen the company's financial position and support its future growth prospects.

The warrant exercise, which involved the issuance of 3,703,703 ordinary shares and an equivalent number of warrants, was priced at a combined public offering price of $1.35 per ordinary share and accompanying warrant. Each warrant is designed with a five-year expiration timeline from the date of issuance and an exercise price that mirrors the offering price at $1.35. Notably, the warrants are immediately exercisable upon issuance, allowing investors to gain exposure to the potential upsides of Silexion's promising pipeline.

The completion of this offering is anticipated to close on or about January 17, 2025, contingent upon standard closing conditions being met. This process adds a layer of security for both the issuer and the investors involved.

Silexion Therapeutics is on the cusp of a pivotal moment as it seeks to enhance its financial resources to support the development of its RNAi therapies. The therapeutic landscape for KRAS-driven cancers remains one of the most challenging areas in oncology, making breaks in research and clinical intervention all the more critical. With a clear focus on employing RNAi technology, Silexion aims to disrupt the molecular mechanisms that underlie these aggressive cancer types, potentially transforming therapeutic approaches and patient outcomes.

As investor interest burgeons in the biotech sector, particularly within areas of high unmet medical need, Silexion's offering can be seen as an essential step to further solidify its role in the fight against cancer. The anticipated funds will likely aid in advancing clinical trials and expanding the company's research capabilities as it works diligently to bring novel therapies to market.



In recent months, Silexion Therapeutics has made significant strides in advancing its research and development efforts. In December 2024, the company announced a strategic collaboration with Evonik to develop an advanced siRNA formulation for KRAS-mutated cancers. This collaboration leverages Evonik's proprietary biodegradable long-acting PLGA (RESOMER®) microparticle formulation, which has demonstrated high efficacy in preclinical models using mice with human pancreatic tumor cell lines carrying various KRAS mutations. By employing Evonik's formulation expertise, Silexion aims to deliver sustained-release RNAi therapy, allowing for more effective targeting of KRAS mutations—one of the most challenging genetic drivers in oncology.



Moreover, Silexion Therapeutics has been actively exploring strategic partnerships and collaborations to further its mission. In November 2024, the company announced a merger with Moringa Acquisition Corp, leading to the launch of SLXN and SLXNW on the Nasdaq. This strategic move positioned Silexion Therapeutics as a publicly-traded company, providing it with access to additional capital and resources to support its research and development efforts.

As Silexion Therapeutics navigates the upcoming phases of its development and throughput of its clinical programs, the prospect of delivering effective treatment options for patients with KRAS-driven cancers highlights the company's commitment to oncology innovation and patient care. The market will be watching closely as the company leverages this funding to push the boundaries of what's possible in cancer treatment.

In conclusion, Silexion Therapeutics' warrant exercise for approximately $3.3 million is a strategic move that bolsters the company's financial position and supports its future growth prospects. With a focus on developing innovative RNAi therapies for KRAS-driven cancers, Silexion Therapeutics is well-positioned to make a significant impact in the competitive field of cancer therapeutics.